期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

哺乳动物雷帕霉素靶蛋白抑制剂用于多重靶向治疗耐药的HER-2阳性晚期乳腺癌一例 被引量：1

原文传递
导出
摘要 在HER-2阳性晚期乳腺癌的临床治疗中，抗HER-2靶向药物曲妥珠单克隆抗体（赫赛汀）及拉帕替尼的应用显著改善了患者的无进展生存期（progression—freesurvival，PFS）和0S[1]，然而，有些患者在接受靶向治疗过程中先后出现曲妥珠单克隆抗体及拉帕替尼治疗耐药，
作者 边莉 郭芸菲 张会强 王涛 江泽飞
机构地区 军事医学科学院附属医院乳腺肿瘤内科
出处 《中华乳腺病杂志（电子版）》 CAS 2013年第5期58-58,62,共2页 Chinese Journal of Breast Disease(Electronic Edition)
关键词 抗药性 耐药 乳腺肿瘤 MTOR抑制剂 曲妥珠单克隆抗体 拉帕替尼
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1江泽飞,邵志敏,徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识[J].中华肿瘤杂志,2010,32(2):158-160. 被引量：49
  • 2王涛,江泽飞.乳腺癌分子靶向治疗进展、困境和出路[J].中华乳腺病杂志（电子版）,2011,5(5):4-8. 被引量：6
  • 3Wang L, Zhang Q, Zhang J, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib [ J ]. BMC Cancer,2011,11:248.
  • 4Lu CH, Wyszomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency [ J 1- Clin Cancer Res, 2007,13(19) :5883-5888.
  • 5Meric-Bemstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy [ J ]. J Clin Oncol,2009, 27 ( 13 ) :2278-2287.
  • 6Nahta R, O' Regan RM. Evolving strategies for overcoming resistance to HER-2-directed therapy: targeting the PI3K/Akt/ mTOR pathway[ J ]. Clin Breast Cancer, 2010,10 ( Suppl 3 ) : $72-78.
  • 7Gayle SS, Arnold SL, O' Regan RM, et al. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER-2- overexpressing breast cancer cells with primary trastuzumab resistance[ J ]. Anticancer Agents Med Chem, 2012, 12 ( 2 ) : 151-162.

二级参考文献37

  • 1王涛,江泽飞,宋三泰,刘晓晴,于静新,刘芳,闫敏.单药赫赛汀~治疗复发转移性乳腺癌[J].中华肿瘤杂志,2004,26(7):430-432. 被引量：25
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：167
  • 3Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 2007, 25 : 118-145.
  • 4Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science, 1987, 235 : 177-182.
  • 5Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med, 2001, 344:783- 792.
  • 6Marty M, Cognetti F, Maraninehi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23: 4265 -4274.
  • 7Papaldo P, Fabi A, Ferretti G, et al. A phase Ⅱ study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol, 2006, 17: 630-636.
  • 8Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ⅲ TANDEM study. J Clin Oncol, 2009, 27:5529-5537.
  • 9von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol, 2009, 27: 1999- 2006.
  • 10Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 2008, 112:533-543.

共引文献53

同被引文献44

  • 1Ross JS,Fletcher JA.The HER-2/neu oncogene in breast cancer:prognostic factor,predictive factor,and target for therapy[J].Stem Cells,1998,16 (6):413-428.
  • 2Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11):783-792.
  • 3Wong H,Leung R,Kwong A,et al.Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2 + metastatic breast cancer[J].Oncologist,2011,16(11):1535-1546.
  • 4Sáez R,Molina MA,Ramsey EE,et al.p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer[J].Clin Cancer Res,2006,12(2):424-431.
  • 5Scaltriti M,Rojo F,Oca(n)a A,et al.Expression of p95HER2,a truncated form of the HER2 receptor,and response to antiHER2 therapies in breast cancer[J].J Natl Cancer Inst,2007,99(8):628-638.
  • 6Sperinde J,Jin X,Banerjee J,et al.Quantitation of p95 HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients[J].Clin Cancer Res,2010,16 (16):4226-4235.
  • 7Hynes NE,Lane HA.ERBB receptors and cancer:the complexity of targeted inhibitors[J].Nat Rev Cancer,2005,5(5):341-354.
  • 8Frogne T,Laenkholm AV,Lyng MB,et al.Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors[J].Breast Cancer Res,2009,11(1):R11.
  • 9Desmedt C,Sperinde J,Piette F,et al.Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH[J].Diagn Mol Pathol,2009,18(1):22-29.
  • 10Toi M,Sperinde J,Huang W,et al.Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer[J].BMC Cancer,2010,10:56.

引证文献1

二级引证文献1

中华乳腺病杂志（电子版）
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部